论文部分内容阅读
目的探讨曲美他嗪联合阿托伐他汀治疗冠心病的临床疗效及安全性。方法 78例冠心病患者,随机将患者分为观察组(40例)和对照组(38例)。两组均常规给予曲美他嗪治疗,观察组在此基础上加用阿托伐他汀,评价两组临床疗效及不良反应。结果两组治疗后C反应蛋白(CRP)、血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)等指标水平均较治疗前下降,左室射血分数(LVEF)则明显上升,治疗前后对比差异均有统计学意义(P<0.05)。观察组LVEF、CRP、TC、LDL-C改善程度明显优于对照组(P<0.05)。两组心性事件发生率对比差异有统计学意义(P<0.05)。两组随访均未出现死亡病例。结论较单纯曲美他嗪用药治疗,曲美他嗪联合他汀类药物更利于增强药效,改善心功能状况,且安全有保障,是比较理想的联合用药方法。
Objective To investigate the clinical efficacy and safety of trimetazidine combined with atorvastatin in the treatment of coronary heart disease. Methods 78 patients with coronary heart disease were randomly divided into observation group (40 cases) and control group (38 cases). Trimetazidine was given routinely in both groups. Atorvastatin was added to the observation group to evaluate the clinical efficacy and adverse reactions in both groups. Results After treatment, the CRP, TC and LDL-C levels decreased in both groups before treatment and LVEF increased significantly Before and after treatment, the differences were statistically significant (P <0.05). The improvement of LVEF, CRP, TC, LDL-C in the observation group was significantly better than that in the control group (P <0.05). There was significant difference between the two groups in the incidence of cardiac events (P <0.05). No deaths occurred in either group. Conclusion Compared with trimetazidine alone, trimetazidine combined with statins is more beneficial to enhance the efficacy, improve cardiac function, and is safe and secure, which is an ideal combination therapy.